A Target Occupancy Study With Ritlecitinib.
NCT05128058
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy
Interventions
DRUG:
Ritlecitinib 50 mg
DRUG:
Ritlecitinib 200 mg
Sponsor
Pfizer